FDA Drug Approval Process

FDA | April 25, 2018

article image
This infographic, created by the US Food and Drug Administration (FDA), outlines the regulatory steps involved when developing a drug, from initial development of the compound through to its approval.

Spotlight

Porton Biopharma Ltd

Porton Biopharma Limited (PBL) is a UK based company experienced in developing, manufacturing and bringing to market biopharmaceutical therapeutics and vaccines. PBL was corporatised out of Public Health England on 1st April 2015 to enable us to be better placed to grow our business, which is built upon decades of biopharmaceutical experience including the successful commercialisation and licensure of many therapies which now save thousands of lives every year, and generate revenues from world-wide sales.

OTHER ARTICLES

3 Big Pharma Stocks Plunging the Most During the Coronavirus Stock Market Crash: Are They Buys?

Article | March 26, 2020

Big pharma stocks have been clobbered during the coronavirus-caused stock market crash. You can count the number of drugmakers with market caps of $25 billion or more whose shares haven't dropped by double-digit percentages on one hand -- and have several fingers left over. Three big pharma stocks have plunged the most: AbbVie (NYSE:ABBV), Bristol Myers Squibb (NYSE:BMY), and Pfizer (NYSE:PFE). But are these stocks smart picks to buy right now?

Read More

WANT LESS “LIABILITY” AND MORE “RELIABILITY” FROM YOUR CLINICAL MOBILITY SOLUTION?

Article | March 26, 2020

I recently discussed the different ways that consumer-grade smartphones can compromise patients’ health, safety and overall care. However, some clinicians and healthcare administrators have indicated in recent months that they need help selecting the right enterprise-grade mobility solutions for their unique operating models and workflows. There are many different hardware and software options, and a single rugged device can come in multiple configurations. So, how do you know if you’re picking the right communication tools for your clinicians? The key is to first set performance expectations for the total mobility solution rather than the device alone.

Read More

Advance Your Pharma Supply Chain Planning during a Pandemic

Article | March 26, 2020

One predominant and common element within our pharmaceutical industry, is our devotions to patients. Within supply chain there is always a focus on ensuring the right product is delivered to the right place at the right time in order to ensure patient safety and the continuity of medicinal supplies. With the spread of COVID-19 across 117 countries and counting, every supply chain needs to evaluate their global footprint and develop contingency plans within their end to end operations.

Read More

How Can Medical Cannabis Help to Manage Pain Conditions? – The Cannabis Exchange

Article | March 26, 2020

Pain management is one of the most common reasons for the use of medical cannabis products. However, despite many jurisdictions – including Canada, Germany, and the Netherlands – now allowing the prescription of medical cannabis for this purpose, there remains little ‘high-quality’ evidence to support, or oppose its efficacy. Madden et al. (2018) set out to review the evidence available in order to determine the efficacy of medical cannabis when employed in the management of various forms of musculoskeletal pain. The researchers analysed various studies that assessed the use of cannabinoids in the treatment of arthritis pain; back pain; postoperative pain; and trauma-related pain. It is estimated that up to 30% of the population may suffer from a non-cancer-related pain condition. As such a high percentage of people suffer from these conditions, the development of simple and safe therapies is an essential area of research. This is particularly important as the therapeutic options for people with chronic pain are increasingly limited.

Read More

Spotlight

Porton Biopharma Ltd

Porton Biopharma Limited (PBL) is a UK based company experienced in developing, manufacturing and bringing to market biopharmaceutical therapeutics and vaccines. PBL was corporatised out of Public Health England on 1st April 2015 to enable us to be better placed to grow our business, which is built upon decades of biopharmaceutical experience including the successful commercialisation and licensure of many therapies which now save thousands of lives every year, and generate revenues from world-wide sales.

Events